Nasdaq IPOs

CC Neuberger Principal Holdings I (PCPL.U), a blank check company formed by CC Capital and Neuberger Berman, amended the terms of its upcoming IPO to be more favorable to new investors. In its latest filing, the company also added UBS Investment Bank and Nomura as underwriters. T

Albertsons (ACI), a US grocer operating under Albertsons, Safeway, and other banners, announced last week that it would hold a conference call on April 30 to discuss financial results for its fiscal fourth quarter ended February 29. An IPO could soon follow. Albertsons filed publ

ORIC Pharmaceuticals, a Phase 1 biotech developing small molecule therapies for treatment-resistant cancers, increased the proposed share offering for its upcoming IPO on Thursday. The South San Francisco, CA-based company now plans to raise $94 million by offering 6.3 million sh

1847 Goedeker, which operates an e-commerce platform for appliances and home goods, filed on Wednesday with the SEC to raise up to $11.5 million in an initial public offering. Operating under the name Goedeker's, the company sells home appliances (80% of 2019 revenue), furniture

Social Capital Hedosophia Holdings III, the third blank check company formed by Social Capital and Hedosophia targeting a non-US tech business, raised $720 million by offering 72 million units at $10 to command a market value of $870 million. The company originally planned to off

Social Capital Hedosophia Holdings III, the third blank check company formed by Social Capital and Hedosophia targeting a non-US tech business, is expected to price on Tuesday, April 21, 2020. The Palo Alto, CA-based company plans to raise $600 million by offering 60 million unit

ORIC Pharmaceuticals, a Phase 1 biotech developing small molecule therapies for treatment-resistant cancers, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At

Updated on Monday, April 20, 2020. One biotech IPO is scheduled for the week ahead, and pipeline activity indicates that a few more may be on the way.ORIC Pharmaceuticals (ORIC), a Phase 1 biotech developing small molecule therapies for treatment resistant cancers, plans to

No IPOs are scheduled for the week ahead, though pipeline activity indicates that some may be on the way. Three out of the four IPOs since the second week of March have been biotechs, the sole exception being Chinese AR software company Wimi Hologram Cloud (WIMI). Oncology biotec

There were no IPOs this past week, but initial filings from a biotech and a Chinese issuer are keeping the IPO market moving. After another strong week, the IPO Index is now up about 35% from its March lows. As we pointed out in our 1Q20 IPO Review, the first IPOs to emerge from

Kingsoft Cloud Holdings, a Chinese cloud services and infrastructure provider being spun out of Kingsoft, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Kingsoft Cloud is part of Chinese software franchise Kingsoft Group and is the th

In early April, a short seller accused Chinese coffee chain Luckin (LK) of massively overstating revenues. A day later Chinese education provider TAL reported a non-material overstatement of revenues by an errant employee. Are these two instances leading indicators of financ

Lantern Pharma, a clinical stage oncology biotech using machine learning for drug discovery, filed on Thursday with the SEC to raise up to $29 million in an initial public offering. The company's AI platform, RADR, allows Lantern Pharma to identify potential therapies which were

Luckin Coffee's (LK) alleged financial fraud and decline from an investor favorite to a penny stock is only the tip of the iceberg for the generally poor performance and Western investor skepticism of Chinese IPOs.The latest in a series of setbacks  Even before the specter o

There are no IPOs scheduled for the week ahead.The most likely April IPOs Despite the encouraging market rally this past week, the Renaissance IPO Volatility Index is still about double the five-year average and few companies have filed, indicating the IPO market’s slow Apr

Another biotech IPO has beaten the market blues. Keros Therapeutics (KROS) finished the week up 35%, affirming that the biotech industry won’t be deterred by current market volatility. Oncology biotech Keros Therapeutics priced its upsized IPO at the high end to raise $96 m

Another biotech IPO has beaten the market blues. Keros Therapeutics (KROS) popped 26% on its first day of trading, affirming that the biotech industry won’t be deterred by current market conditions. Oncology biotech Keros Therapeutics priced its upsized IPO at the high end

For years, the VC community bashed the IPO market and its public investors as being too myopic and tied to old-fashioned metrics to appreciate the inflated valuations of giant technology unicorns in which the VCs had invested billions.

Keros Therapeutics, a Phase 1 biotech developing therapies for blood and musculoskeletal disorders, raised $96 million by offering 6.0 million shares at $16, the high end of the range of $14 to $16. Keros upsized its offering by 1.0 million shares (20%). Keros Therapeutics plans

To Prosperity Technology, which provides auto loan services for ridesharing drivers in Sichuan, China, withdrew its plans for an initial public offering on Tuesday. It originally filed in May 2019 with a proposed deal size of $8 million. The Sichuan, China-based company was found